We are live on ! Find out more
TSC

Two Seas Capital Portfolio holdings

AUM $7.15B
1-Year Est. Return 169.27%
This Fund
S&P 500
This Quarter Est. Return
-3.71%
1 Year Est. Return
+169.27%
3 Year Est. Return
+279.82%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$410M
AUM Growth
-$87.8M
Cap. Flow
-$14.4M
Cap. Flow %
-3.51%
Top 10 Hldgs %
99.03%
Holding
14
New
–
Increased
5
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$5.78M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$2.5M
3
ABUS icon
Arbutus Biopharma
ABUS
+$1.49M
4
MMM icon
3M
MMM
+$1.42M
5
ESPR
Esperion Therapeutics
ESPR
+$18.1K

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$8.41M
2
META icon
Meta Platforms (Facebook)
META
+$3.26M
3
SONO icon
Sonos
SONO
+$3.05M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$875K
5
HTZWW
Hertz Global Holdings Warrants
HTZWW
+$539K

Sector Composition

Rank Sector Weight
1 Healthcare 88%
2 Industrials 4.06%
3 Communication Services 2.26%
4 Materials 1.56%
5 Technology 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INDV icon
1
Indivior Pharmaceuticals
INDV
$4.58B
$211M 51.5%
13,810,893
+140,581
+1% +$2.5M
ROIV icon
2
Roivant Sciences
ROIV
$25B
$95.5M 23.33%
8,508,223
+592,991
+7% +$5.78M
ESPR
3
DELISTED
Esperion Therapeutics
ESPR
$23M 5.61%
7,686,120
+13,950
+0.2% +$18.1K
ABUS icon
4
Arbutus Biopharma
ABUS
$913M
$22.6M 5.52%
9,041,927
+761,109
+9% +$1.49M
MMM icon
5
3M
MMM
$93.9B
$15.8M 3.86%
173,168
+17,688
+11% +$1.42M
META icon
6
Meta Platforms (Facebook)
META
$1.5T
$9.26M 2.26%
26,175
-10,000
-28% -$3.26M
IMVT icon
7
Immunovant
IMVT
$8.06B
$8.37M 2.04%
198,752
-228,504
-53% -$8.41M
OMEX icon
8
Odyssey Marine Exploration
OMEX
$43.5M
$6.38M 1.56%
1,371,874
– –
IMVT icon
9
CALL
Immunovant
IMVT
$8.06B
$3.65M 0.89%
86,600
– –
SONO icon
10
Sonos
SONO
$1.88B
$3.08M 0.75%
179,732
-226,440
-56% -$3.05M
HTZ icon
11
Hertz
HTZ
$493M
$802K 0.2%
77,188
-10,000
-11% -$96.6K
HTZWW
12
Hertz Global Holdings Warrants
HTZWW
$67.7M
$92.3K 0.02%
16,841
-106,653
-86% -$539K
ARQT icon
13
Arcutis Biotherapeutics
ARQT
$3.39B
– –
-164,807
Closed -$875K

Similar funds

UB
UMB Bank Kansas City, Missouri $7.16B AUM 20.88% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.17B AUM 17.27% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $7.13B AUM 35.47% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Two Seas Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Two Seas Capital held 14 positions worth $410M, down 18% from $497M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Two Seas Capital withdrew a net $14.4M in Q4 2023, closing 1 position and reducing 5 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $875K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Two Seas Capital added an estimated $5.78M to Roivant Sciences.

  • Two Seas Capital added most to Roivant Sciences in Q4 2023, an estimated $5.78M increase.
  • Two Seas Capital's biggest Q4 2023 reduction was Immunovant, cutting an estimated $8.41M.
  • Two Seas Capital fully exited Arcutis Biotherapeutics in Q4 2023, selling an estimated $875K.
  • Two Seas Capital's ten largest holdings make up 99% of its $410M portfolio in Q4 2023.
  • Two Seas Capital opened 0 new positions and closed 1 in Q4 2023.
  • Two Seas Capital's portfolio value fell 18% quarter-over-quarter to $410M.

Based on Two Seas Capital's 13F filing for Q4 2023, filed 14 Feb 2024.